Vitamin A

證據等級: L5

預測適應症: 10 個

Vitamin A: From Nutritional Deficiency to Congenital Prothrombin Deficiency

One-Sentence Summary

Vitamin A (retinol) is an essential fat-soluble micronutrient clinically used in the prevention and treatment of vitamin A deficiency, night blindness, and immune dysfunction, with its active metabolite retinoic acid also used in dermatological and oncological conditions. The TxGNN model predicts it may be effective for Congenital Prothrombin Deficiency (hereditary Factor II deficiency), with a prediction score of 99.97%. However, no supporting clinical trials or literature directly link Vitamin A to this indication, and the mechanistic basis is biologically implausible — this prediction most likely reflects indirect knowledge graph linkages between vitamins and the coagulation pathway rather than a genuine repurposing opportunity.

Quick Overview

Item	Content
Original Indication	Vitamin A deficiency; night blindness; immune dysfunction; epithelial maintenance
Predicted New Indication	Congenital Prothrombin Deficiency
TxGNN Prediction Score	99.97%
Evidence Level	L5
Philippines Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Vitamin A in this context. Based on known information, Vitamin A (retinol) is the precursor to retinoic acid, which exerts its biological effects primarily through nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR). These receptors regulate a broad range of genes involved in cellular differentiation, epithelial integrity, immune modulation, and — via its active metabolite all-trans retinoic acid (ATRA) — cell cycle arrest and apoptosis in specific malignancies.

Congenital prothrombin deficiency is a rare autosomal recessive bleeding disorder caused by mutations in the F2 gene, resulting in reduced synthesis or function of prothrombin (Factor II). Prothrombin is a Vitamin K–dependent coagulation factor; its biological activation requires carboxylation of glutamate residues by Vitamin K–dependent carboxylase — a mechanism entirely distinct from Vitamin A/RAR/RXR signaling. There is no established biochemical pathway by which retinol or retinoic acid would enhance prothrombin gene expression or correct Factor II deficiency.

The TxGNN model’s high-confidence prediction is therefore likely an artifact of indirect connections in the knowledge graph (e.g., broad “vitamin → gene regulation → coagulation” linkages), rather than direct biological plausibility. This prediction should be treated as a hypothesis-generating signal that requires mechanistic validation before further development.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00562783	Phase 2	Completed	90	Vitalliver in decompensated cirrhosis — intervention is not Vitamin A; no direct relevance to prothrombin deficiency
NCT04384341	N/A	Recruiting	480	PHILEOS study: haemophilia and bone mineral density — studies Factor VIII/IX deficiency, not Factor II; Vitamin A not evaluated
NCT02392767	N/A	Completed	25	Multi-vitamin dietary supplement for endothelial function in hypertension — unrelated to congenital coagulation disorders
NCT00168077	Phase 3	Completed	40	BERIPLEX P/N (prothrombin complex concentrate) for acquired Factor II/VII/IX/X deficiency — intervention is prothrombin concentrate, not Vitamin A
NCT03534752	N/A	Completed	220	Retrospective registry of adult inborn errors of metabolism in French-speaking Switzerland — observational only, no Vitamin A intervention

Note: None of these trials investigate Vitamin A for congenital prothrombin deficiency. All five trials were incidentally retrieved and are assessed as Grade C relevance (not directly applicable).

Literature Evidence

Currently no related literature available for Vitamin A in congenital prothrombin deficiency.

Philippines Market Information

Vitamin A (DB00162) currently has no registered products with the Philippine FDA. No authorization records, dosage forms, or approved indications are on file.

Safety Considerations

Please refer to the package insert for safety information.

Known general considerations for Vitamin A: teratogenicity risk at high doses (particularly in pregnancy), hepatotoxicity with chronic excessive intake, and potential for hypervitaminosis A (headache, bone pain, liver damage). Formal Philippines-specific warnings and contraindications are unavailable pending package insert review.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical, mechanistic, or translational evidence supporting Vitamin A in congenital prothrombin deficiency. The TxGNN score (99.97%), while superficially high, reflects indirect knowledge graph connectivity — Vitamin A’s RAR/RXR signaling has no known influence on Vitamin K–dependent Factor II synthesis, and the five retrieved clinical trials are all irrelevant to this indication.

To proceed, the following is needed:

Identify a biologically plausible link between Vitamin A/retinoic acid signaling (RAR/RXR) and Factor II (prothrombin) gene expression — no such mechanism is currently known
Commission preclinical studies (hepatocyte models, F2-knockout mice) to test whether retinoid supplementation affects prothrombin levels
Obtain Vitamin A mechanism of action (MOA) data from DrugBank API to identify any coagulation-related gene targets
Review Philippines FDA package insert and TFDA package insert for full safety profile (warnings, contraindications)
Consider prioritizing higher-evidence TxGNN predictions instead: cell proliferation disorder (Rank 5, L2, Proceed with Guardrails), perinatal disease (Rank 7, L2, Proceed with Guardrails), and radiation or chemically induced disorder (Rank 10, L2, Proceed with Guardrails) all show substantially stronger clinical evidence bases for Vitamin A repurposing
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.